Cyrielle Gilletta

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <scp>OBSERV</scp>‐<scp>IBD</scp> cohort

S. Tadbiri, Laurent Peyrin‐Biroulet, Mélanie Serrero et al. · Alimentary Pharmacology & Therapeutics · 2017 · 112 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Édouard Louis, Matthieu Resche‐Rigon, David Laharie et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 108 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study

Aurélien Amiot, Jérôme Filippi, Véred Abitbol et al. · Alimentary Pharmacology & Therapeutics · 2020 · 84 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy

Uri Kopylov, Jurij Hanžel, Claire Liefferinckx et al. · Alimentary Pharmacology & Therapeutics · 2020 · 80 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +5